Effects of growth hormone (GH) replacement therapy on very low density lipoprotein apolipoprotein B100 kinetics in patients with adult GH deficiency: A stable isotope study

Journal of Clinical Endocrinology and Metabolism

Volumn 84, Issue 1, 1999, Pages 307-316

  Christ, E R ^a,c   Cummings, M H ^a   Albany, E ^a   Umpleby, A M ^d   Lumb, P J ^a   Wierzbicki, A S ^a   Naoumova, R P ^b   Boroujerdi, M A ^a   Sonksen P H ^a   Russell Jones, D L ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

^c GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B100; CHOLESTEROL; HEMOGLOBIN A1C; HUMAN GROWTH HORMONE; INSULIN; LOW DENSITY LIPOPROTEIN RECEPTOR; SOMATOMEDIN; STABLE ISOTOPE; VERY LOW DENSITY LIPOPROTEIN;

ADULT; AGED; ARTICLE; BODY FAT; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG TOLERABILITY; FEMALE; GROWTH HORMONE DEFICIENCY; HEMOGLOBIN DETERMINATION; HORMONE SUBSTITUTION; HUMAN; INSULIN BLOOD LEVEL; LIPID BLOOD LEVEL; LIPID COMPOSITION; LIPOPROTEIN METABOLISM; MALE; MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEIN METABOLISM; PROTEIN SECRETION; RANDOMIZED CONTROLLED TRIAL; RECEPTOR UPREGULATION; SUBCUTANEOUS DRUG ADMINISTRATION;

ADULT; AGED; APOLIPOPROTEIN B-100; APOLIPOPROTEINS B; BODY COMPOSITION; DOUBLE-BLIND METHOD; FATTY ACIDS, NONESTERIFIED; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HORMONE REPLACEMENT THERAPY; HUMAN GROWTH HORMONE; HUMANS; INSULIN; LIPOPROTEINS, VLDL; MALE; MEVALONIC ACID; MIDDLE AGED;

EID: 0032925650     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.84.1.307     Document Type: Article

References (42)

1. 1. Rosen T, Bengtsson B-Å. 1990 Premature mortality due to cardiovascular disease in hypopituitarism. Lancet. 336:285-288.
2. 2. Bülow B, Hagmar L, Mikozy Z, Nordstroem CH, Erfurth EM. 1997 Increased cerebrovascular mortality in patients with hypopituitarism. Clin Endocrinol (Oxf). 46:75-81.
3. 3. Markussis V, Beshyah SA, Fisher C, Sharp P, Nicolaides AN, Johnston DG. 1992 Detection of premature atherosclerosis by high-resolution ultrasonography in symptom-free hypopituitary adults. Lancet. 340:1188-1192.
4. 4. Shahi M, Beshyah SA, Hackett D, Sharp PS, Johnston DG, Foale RA. 1992 Myocardial dysfunction in treated adult hypopituitarism: a possible explanation for increased cardiovascular mortality. Br Heart J. 67:92-96.
5. 5. Rosen T, Eden S, Larson G, Wilhelmsen L, Bengtsson B-Å. 1993 Cardiovascular risk factors in adult patients with growth hormone deficiency. Acta Endocrinol (Copenh). 129:195-200.
6. 6. Salomon F, Cuneo RC, Hesp R, Sönksen PH. 1989 The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency. N Engl J Med. 321:1797-1803.
7. 7. Attanasio AF, Lamberts SWJ, Matranga AMC, et al. 1997 Adult growth hormone-deficient patients demonstrate heterogenity between childhood on-set and adult onset before and during human GH treatment. J Clin Endocrinol Metab. 82:82-88.
8. 8. Cummings MH, Watts GF, Umpleby AM, Hennessy TR, Naoumova RP, Sönksen PH. 1995 Increased hepatic secretion of very low density lipoprotein apolipoprotein B100 in obesity: a stable isotope study. Clin Sci. 88:225-233.
9. 9. Cummings MH, Watts GF, Umpleby AM, Hennessy TR, Quiney JR, Sönksen PH. 1995 Increased hepatic secretion of very low density lipoprotein apolipoprotein B100 in heterozygous familial hypercholesterolaemia: a stable isotope study. Atherosclerosis. 113:79-89.
10. 10. Cummings MH, Watts GF, Umpleby AM, et al. 1995 Increased hepatic secretion of very low density lipoprotein apolipoprotein B100 in NIDDM. Diabetologia. 38:959-967.
11. 11. Kesäniemi YA, Beltz WF, Grundy SM. 1985 Comparisons of metabolism of apolipoprotein B in normal subjects, obese patients, and patients with cornary heart disease. J Clin Invest. 76:586-595.
12. 12. Cummings MH, Christ ER, Umpleby AM, et al. 1997 Abnormalities of very low density lipoprotein apolipoprotein B 100 metabolism contribute to the dyslipidaemia of adult growth hormone deficiency. J Clin Endocrinol Metab. 82:2010-2013.
13. 13. Sniderman AD, Cianflone K. 1993 Substrate delivery as a determinant of hepatic apoB secretion. Arterioscler Thromb. 13:629-636.
14. 14. Dixon JL, Ginsberg HN. 1993 Regulation of hepatic secretion of apolipoprotein B-containing lipoproteins: information obtained from cultured liver cells. J Lipid Res. 34:167-179.
15. 15. Angelin B, Rudling M. 1994 Growth hormone and hepatic lipoprotein metabolism. Curr Opin Lipidol. 5:160-165.
16. 16. Vikman-Adolfsson K, Oscarsson J, Nilson-Ehle P, Eden S. 1994 Growth hormone but not gonadal steroids influence lipoprotein lipase and hepatic lipase activity in hypophysectomized rats. J Endocrinol. 140:203-209.
17. 17. Asayama K, Amemiya S, Kusano S, Kato K. 1984 Growth-hormone induced changes in postherparin and hepatic triglyceride lipase activities. Metabolism. 33:129-131.
18. 18. Ottoson M, Vikman-Adolfsson K, Enerbäck S, Elander A, Björntorp P, Eden S. 1995 Growth hormone inhibits lipoprotein lipase activity in human adipose tissue. J Clin Endocrinol Metab. 80:936-941.
19. 19. Packard JP, Shepherd J. 1997 Lipoprotein heterogenity and apolipoprotein B metabolism. Arterioscler Thromb Vasc Biol. 17:3542-3556.
20. 20. Rudling M, Norstedt G, Olivecrona H, Reihner E, Gustafsson J-A, Angelin B. 1992 Importance of growth hormone for the induction of hepatic low density lipoprotein receptor. Proc Natl Acad Sci USA. 89:6983-6987.
21. 13C]leucine infusion in man: a method for measuring human intracellular leucine tracer enrichment. Metabolism. 31:1105-1112.
22. 22. International Committee for Standardization in Hematology. 1973 Standard techniques for the measurement of red-cell and plasma volume. A report by the international committee for standardization in haematology (ICSH): panel of diagnostic applications of radioisotopes in haematology. Br J Haematol. 25:801-814.
23. 23. De Boer H, Blok GJ, Van der Veen EA. 1995 Clinical aspects of growth hormone deficieny in adults. Endocr Rev. 16:63-85.
24. 24. Karte JP, Sata T, Hamilton RL. 1975 Apoprotein composition of very low density lipoproteins of human serum. J Clin Invest. 56:1622-1634.
25. 25. Cummings MH, Watts GF, Lumb PJ, Slavin BM. 1994 Comparison of immunoturbimetric and Lowry methods tor measuring concentration of very low density lipoprotein apolipoprotein B-100 in plasma. J Clin Pathol. 47:176-178.
26. 26. Sönksen PH. 1976 Double antibody technique for the simultaneous assay of insulin and growth hormone. In: Antoniades H, ed. Hormones in human blood: detection assay. Cambridge: Harvard University Press; 176-199.
27. 27. Teale JD, Marks V. 1990 Inappropriately elevated plasma insulin-like growth factor II in relation to suppressed insulin-like growth factor I in the diagnosis of non-islet cell tumor hypoglycaemia. Clin Endocrinol (Oxf). 33:97-98.
28. 28. Scoppola A, Maher VMG, Thompson GR, Rendell NB, Taylor GW. 1991 Quantification of plasma mevalonic acid using gas chromatography-electron capture mass spectrometry. J Lipid Res. 32:1057-1060.
29. 29. Menzel HJ, Utermann G. 1986 Apolipoprotein E phenotyping from serum Western blotting. Electrophoresis. 7:492-495.
30. 30. Cobelli C, Toffolo G, Foster DM. 1992 Tracer-to-tracee ratio for analysis of stable isotope tracer data:link with radioactive kinetic formalism. Am J Physiol. 262:E968.
31. 31. Carroll PV, Christ ER, Members of Growth Hormone Research Society Scientific Committee. 1998 Growth hormone deficiency in adulthood and the effects of growth hormone replacement: a review. J Clin Endocrinol Metab. 83:382-395.
32. 32. Fowelin J, Attvall S, Lager I, Bengtsson B-Å. 1993 Effects of treatment with recombinant human growth hormone on insulin sensitivity and glucose metabolism in adults with growth hormone deficiency. Metab Clin Exp. 42:1443-1447.
33. 33. Bengtsson B-Å, Eden S, Lonn L, et al. 1993 Treatment of adults with growth hormone deficiency with recombinant human GH. J Clin Endocrinol Metab. 76:309-317.
34. 34. Gibbons GF. 1990 Assembly and secretion of hepatic very low density lipoprotein. Biochem J. 268:1-13.
35. 35. Weiland D, Mondon CE, Reaven GM. 1980 Evidence for multiple causality in the development of diabetic hypertriglyceridaemia. Diabetologia. 18:335-340.
36. 36. Kissebah AH, Alfarsi S, Evans DJ, Adams PW. 1982 Integrated regulation of very low density lipoprotein triglyceride and apolipoprotein B kinetics in non-insulin dependent diabetes mellitus. Diabetes. 31:217-225.
37. 37. Russell-Jones DL, Watts GF, Weissberger A, et al. 1994 The effect of growth hormone replacement on serum lipids, lipoproteins, apolipoproteins and cholesterol precursors in adult growth hormone deficient patients. Clin Endocrinol (Oxf). 41:345-350.
38. 38. Rudling M, Parini P, Angelin B. 1997 Growth hormone and bile acid synthesis. Key role for the activity of hepatic microsomal cholesterol 7α-hydroxylase in the rat. J Clin Invest. 99:2239-2245.
39. 39. Ginsberg HN. 1987 Very low density lipoprotein metabolism in diabetes mellitus. Diabet Metab Rev. 3:571-589.
40. 40. Layman DK, Wolfe RR. 1987 Sample site selection for tracer studies applying a unidirectional circulatory approach. Am J Physiol. 253:E173-E178.
41. 41. Parhofer KG, Barrett PHR, Bier DM, Schonfeld G. 1991 Determination of kinetic parameters of apolipoprotein B metabolism using amino acids labelled with stable isotopes. J Lipid Res. 32:1311-1323.
42. 42. Cummings MH, Watts GF. 1996 Stable isotopes in lipoprotein research: kinetic studies of very low density lipoprotein apolipoprotein B-100 metabolism in human subjects. Endocrinol Metab. 3:73-89.